John T. Greff
Fundador en Sequel Venture Partners LLC .
Perfil
Prior to co-founding Sequel in 1996, Mr. Greff was the former Chief Financial Officer of two venture-backed biotechnology companies, where over eleven years he raised in excess of $200 million in private and public equity.
He was most recently with Allos Therapeutics, Inc., a Denver startup.
Prior to that, he helped build and take public Somatogen, Inc., a Boulder-based bio-pharmaceutical company.
Mr. Greff received a B.S.
in Business Administration from Colorado State University, and an M.B.A.
from the University of Denver.
Cargos activos de John T. Greff
Empresas | Cargo | Inicio |
---|---|---|
Sequel Venture Partners LLC
Sequel Venture Partners LLC Investment ManagersFinance Sequel Venture Partners LLC (Sequel Venture Partners) is a venture capital firm founded in 1996 by Kinney Johnson, Daniel Mitchell and Thomas Washing. The firm is headquartered in Boulder, Colorado. | Fundador | 16/10/2009 |
Boulder Community Health Co.
Boulder Community Health Co. Miscellaneous Commercial ServicesCommercial Services Boulder Community Health Co. is a non-profit, independent, integrated, regional health system that provides high-value healthcare in an innovative, patient-centric environment. The private company is based in Boulder, CO and has subsidiaries in the United States. Boulder Community Health is known for its clinical excellence in heart care, neurosurgery, stroke care, orthopedics, and cancer care. The company has been providing new initiatives ranging from mental health services, a heart failure clinic, a children's hospital, and wellness programs geared towards better health for employees and the community. The CEO of the company is Robert Vissers. | Presidente | - |
SpringTime Ventures LLC
SpringTime Ventures LLC Investment ManagersFinance SpringTime Ventures LLC (SpringTime Ventures) is an independent venture capital firm headquartered in Denver, Colorado. The firm was founded in 2016 by Matt Blomstedt and Rick Patch. | Director Financiero/CFO | - |
Antiguos cargos conocidos de John T. Greff.
Empresas | Cargo | Fin |
---|---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Corporate Officer/Principal | - |
Formación de John T. Greff.
Colorado State University | Undergraduate Degree |
University of Denver | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 4 |
---|---|
Sequel Venture Partners LLC
Sequel Venture Partners LLC Investment ManagersFinance Sequel Venture Partners LLC (Sequel Venture Partners) is a venture capital firm founded in 1996 by Kinney Johnson, Daniel Mitchell and Thomas Washing. The firm is headquartered in Boulder, Colorado. | Finance |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
Boulder Community Health Co.
Boulder Community Health Co. Miscellaneous Commercial ServicesCommercial Services Boulder Community Health Co. is a non-profit, independent, integrated, regional health system that provides high-value healthcare in an innovative, patient-centric environment. The private company is based in Boulder, CO and has subsidiaries in the United States. Boulder Community Health is known for its clinical excellence in heart care, neurosurgery, stroke care, orthopedics, and cancer care. The company has been providing new initiatives ranging from mental health services, a heart failure clinic, a children's hospital, and wellness programs geared towards better health for employees and the community. The CEO of the company is Robert Vissers. | Commercial Services |
SpringTime Ventures LLC
SpringTime Ventures LLC Investment ManagersFinance SpringTime Ventures LLC (SpringTime Ventures) is an independent venture capital firm headquartered in Denver, Colorado. The firm was founded in 2016 by Matt Blomstedt and Rick Patch. | Finance |
- Bolsa de valores
- Insiders
- John T. Greff